Antibodies News and Research

RSS

CGRP inhibitors may reduce glaucoma risk among migraine patients

A type of drug used to prevent migraine may be associated with a reduced risk of glaucoma, according to a study published May 6, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

6 May 2026

H5N1 spreads through multiple routes on infected dairy farms

The H5N1 strain of highly pathogenic avian influenza H5N1 has been detected in over 700 herds of dairy cows in California, the largest dairy-producing state in the U.S.

5 May 2026

Phase 2 human clinical trial paves way for effective hookworm vaccine

A phase 2 human clinical trial of an antigen for a parasitic infection caused by hookworms has been shown to be effective in limiting the intensity of infection, paving the way for the development of a vaccine.

5 May 2026

Multiple myeloma mortality rates decline with advances in targeted therapies

A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023."

29 Apr 2026

Maternal antibodies provide lifelong protection against adult gum disease

Mothers provide a hidden immune legacy that protects their children's teeth long after weaning is over. A new study reveals how maternal antibodies act as early life architects, programming the mouth to resist aggressive bacteria and prevent the bone loss associated with adult gum disease.

29 Apr 2026

New map reveals B cell clusters linked to faster diabetic kidney disease

A detailed new map of the human kidney revealed a previously unrecognized form of diabetic kidney disease (DKD) marked by clusters of immune cells-specifically B cells-that are linked to faster disease progression.

29 Apr 2026

New vaccine strategy neutralizes diverse HIV variants

Researchers at Karolinska Institutet, in collaboration with colleagues at The Scripps Research Institute and Emory University, have developed a new vaccine strategy that has generated antibodies capable of neutralising highly divergent HIV variants.

29 Apr 2026

Addgene reinforces its expanding role in research with new brand

Addgene, a purpose-driven organization that joins with scientists around the world to reduce barriers to research and foster innovation, today announced that its strategic growth and expanded services have driven the organization’s refreshed brand.

29 Apr 2026

Scientists redesign CAR-T cells to fight more than cancer

This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic viral infections, and next-generation immune-cell platforms. It highlights promising engineering advances, including universal CAR-T cells, in vivo delivery, CAR-NK cells, and safety switches, while emphasizing unresolved challenges in durability, safety, scalability, and global access.

29 Apr 2026

Wearable sweat sensor tracks vitamin levels in real time

Researchers developed a wearable electrochemical patch that detects six vitamins in sweat at nanomolar levels, combining sweat induction, microfluidic sampling, wireless readout, and pH/ionic-strength calibration. Human testing focused mainly on vitamin B9, showing sweat levels rose after supplementation or a vitamin B9-rich diet and correlated with serum levels, supporting future use for non-invasive nutrition trend monitoring.

28 Apr 2026

Why H2N2 flu is back on the pandemic preparedness radar

A historical review in Vaccine warns that global H2N2 immunity has sharply declined since the 1957 Asian influenza pandemic, leaving most people without H2-specific protection if the virus re-emerges. The authors highlight animal reservoirs, waning birth-cohort immunity, and modern H2 vaccine platforms as key priorities for pandemic preparedness.

28 Apr 2026

Researchers pioneer breakthrough therapy for life-threatening infections

A revelatory treatment for patients with life-threatening infectious diseases is being pioneered in Melbourne by researchers at The Alfred and Monash University.

25 Apr 2026

Influenza D shows strong potential to spill over to humans

The influenza D virus that researchers say has been flying under the radar since its detection in animals in 2011 can vigorously make copies of itself in human cells and lung tissue samples, a new study shows.

24 Apr 2026

Study reframes Hodgkin lymphoma as a cancer of failed cell development

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an "identity crisis."

24 Apr 2026

Cell squeezing technology offers new breast cancer risk assessment

Researchers at City of Hope, a cancer research and treatment organization, and the University of California, Berkeley, have created a novel microfluidic platform that can assess women's breast cancer risk at the cellular level.

23 Apr 2026

Kenyan bat coronavirus uses human CEACAM6 to enter cells, raising spillover concerns

Researchers screened a phylogenetically diverse panel of alphacoronavirus spike proteins and found that a heart-nosed bat coronavirus from Kenya can use human CEACAM6 to enter cells.

23 Apr 2026

High levels of gut bacterial toxin linked to increased lupus nephritis risk

The body's immune reaction to increased levels of a toxic molecule, part of a bacterial species in the human gut, may reveal who is most at risk of developing lupus nephritis, according to a new study led by NYU Langone Health.

23 Apr 2026

New antibody mechanism selectively suppresses harmful immune responses

The immune system is our frontline protection against infection, continually searching for and destroying unknown pathogens.

22 Apr 2026

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

21 Apr 2026

Early immune responses linked to broadly neutralizing antibodies against HIV

Some people living with HIV develop antibodies capable of neutralizing many different strains of the virus. New research links this to immune responses that occur early in infection.

21 Apr 2026